192 related articles for article (PubMed ID: 16005564)
21. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
Cardozo L; Amarenco G; Pushkar D; Mikulas J; Drogendijk T; Wright M; Compion G;
BJU Int; 2013 May; 111(5):804-10. PubMed ID: 23294801
[TBL] [Abstract][Full Text] [Related]
22. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
Foote J; Glavind K; Kralidis G; Wyndaele JJ
Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219
[TBL] [Abstract][Full Text] [Related]
23. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
Haab F; Stewart L; Dwyer P
Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
[TBL] [Abstract][Full Text] [Related]
24. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
Kaplan SA; Roehrborn CG; Dmochowski R; Rovner ES; Wang JT; Guan Z
Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446
[TBL] [Abstract][Full Text] [Related]
25. Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study.
Wong C; Duggan P
J Obstet Gynaecol; 2009 Jan; 29(1):31-4. PubMed ID: 19280492
[TBL] [Abstract][Full Text] [Related]
26. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P
BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
[TBL] [Abstract][Full Text] [Related]
27. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder.
Cardozo L; Lisec M; Millard R; van Vierssen Trip O; Kuzmin I; Drogendijk TE; Huang M; Ridder AM
J Urol; 2004 Nov; 172(5 Pt 1):1919-24. PubMed ID: 15540755
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
[TBL] [Abstract][Full Text] [Related]
29. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
[TBL] [Abstract][Full Text] [Related]
30. Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis.
Zinner N; Noe L; Rasouliyan L; Marshall T; Runken MC; Seifeldin R
Am J Geriatr Pharmacother; 2009 Dec; 7(6):373-82. PubMed ID: 20129258
[TBL] [Abstract][Full Text] [Related]
31. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia.
Rackley R; Weiss JP; Rovner ES; Wang JT; Guan Z;
Urology; 2006 Apr; 67(4):731-6; discussion 736. PubMed ID: 16618562
[TBL] [Abstract][Full Text] [Related]
32. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
[TBL] [Abstract][Full Text] [Related]
33. Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency.
Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
J Urol; 2013 Jan; 189(1 Suppl):S129-34. PubMed ID: 23234618
[TBL] [Abstract][Full Text] [Related]
34. Solifenacin at 3 years: a review of efficacy and safety.
Pelman RS; Capo JP; Forero-Schwanhaeuser S
Postgrad Med; 2008 Jul; 120(2):85-91. PubMed ID: 18654073
[TBL] [Abstract][Full Text] [Related]
35. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg.
Brunton S; Kuritzky L
Curr Med Res Opin; 2005 Jan; 21(1):71-80. PubMed ID: 15881477
[TBL] [Abstract][Full Text] [Related]
36. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
Chapple CR; Fianu-Jonsson A; Indig M; Khullar V; Rosa J; Scarpa RM; Mistry A; Wright DM; Bolodeoku J;
Eur Urol; 2007 Oct; 52(4):1195-203. PubMed ID: 17574730
[TBL] [Abstract][Full Text] [Related]
37. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
38. Solifenacin for therapy resistant overactive bladder.
Hoebeke P; De Pooter J; De Caestecker K; Raes A; Dehoorne J; Van Laecke E; Vande Walle J
J Urol; 2009 Oct; 182(4 Suppl):2040-4. PubMed ID: 19695608
[TBL] [Abstract][Full Text] [Related]
39. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.
Zinner N; Noe L; Rasouliyan L; Marshall T; Seifeldin R
Curr Med Res Opin; 2008 Jun; 24(6):1583-91. PubMed ID: 18423103
[TBL] [Abstract][Full Text] [Related]
40. [Solifenacin in treatment of the overactive bladder syndrome--diagnosis, clinical management and results].
Slavov Ch; Popov E; Slavov S; Dimitrov R; Doganov N; Chernev T
Akush Ginekol (Sofiia); 2010; 49(3):16-21. PubMed ID: 20734651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]